SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction

Laval, G.; Rousselot, Hubert; Toussaint-Martel, Sophie; Mayer, F.; Terrebonne, Éric; François, Ετιεννε; Brixi, Hédia; Nguyen, Thierry; Bourdeix, I.; Bisot-Locard, S.; Zelek, Laurent

doi:10.1684/bdc.2011.1535

Cited by 38 publications

(32 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In both studies, the efficacy of octreotide was statistically greater in all the parameters of response (reduction in digestive hypersecretion and control of nausea and vomiting). 54–56 A Phase II study demonstrated that a long-acting formulation of octreotide (LAR Depot) in combination with corticosteroids is useful and safe for the treatment of MBO due to peritoneal carcinomatosis 59. A recent review of the literature concludes that despite the limited number of controlled clinical trials, octreotide is the antisecretory agent of choice for the treatment of MBO based on the results from 15 consistent studies and the experience acquired from 20 years of its use 60.…”

Section: Treatmentmentioning

confidence: 99%

“…The initial use of glucocorticoids is recommended due to their antiemetic effect and reduction of intestinal edema, which may facilitate the spontaneous resolution of the occlusive picture 32,50,51. Most researchers recommend the early use of octreotide or an antisecretor drug due to its clear superiority over other anticholinergic drugs 2,54–59. Nasogastric aspiration should only be considered for the treatment of inoperable MBO in the absence of a symptomatic response to polymodal palliative treatment.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution

Tuca

Güell²,

Martinez-Losada³

et al. 2012

CMAR

205

195

View full text Add to dashboard Cite

Malignant bowel obstruction (MBO) is a frequent complication in advanced cancer patients, especially in those with abdominal tumors. Clinical management of MBO requires a specific and individualized approach that is based on disease prognosis and the objectives of care. The global prevalence of MBO is estimated to be 3% to 15% of cancer patients. Surgery should always be considered for patients in the initial stages of the disease with a preserved general status and a single level of occlusion. Less invasive approaches such as duodenal or colonic stenting should be considered when surgery is contraindicated in obstructions at the single level. The priority of care for inoperable and consolidated MBO is to control symptoms and promote the maximum level of comfort possible. The spontaneous resolution of an inoperable obstructive process is observed in more than one third of patients. The mean survival is of no longer than 4–5 weeks in patients with consolidated MBO. Polymodal medical treatment based on a combination of glucocorticoids, strong opioids, antiemetics, and antisecretory drugs achieves very high symptomatic control. This review focuses on the epidemiological aspects, diagnosis, surgical criteria, medical management, and factors influencing the spontaneous resolution of MBO in advanced cancer patients.

show abstract

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution

Tuca

Güell²,

Martinez-Losada³

et al. 2012

CMAR

205

195

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this is the first report of a successful use of lanreotide Autogel in the management of malignant bowel obstruction. Our results indicate that lanreotide Autogel could be used as an alternative to a long-acting formulation of octreotide, which has recently shown efficacy in the symptomatic treatment of inoperable malignant bowel obstruction due to peritoneal carcinomatosis [ 10 ]. A long-term treatment with lanreotide, as reported herein, is further supported by the results of a study in which 3 patients with malignant bowel obstruction due to ovarian cancer received a monthly-administered long-acting depot form of octreotide (Sandostatin LAR® Depot) for a period of over 9 months, with no significant toxicities reported [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma

Lybaert¹

2014

Case Rep Oncol

View full text Add to dashboard Cite

Intestinal obstruction is a common complication in patients with advanced abdominal or pelvic cancer. The synthetic somatostatin analogue octreotide can help relieve nausea, vomiting and pain in patients with inoperable obstruction. Here, we report a case of recurrent intestinal obstruction in a patient with adenocarcinoma. Although the obstruction was resolved after 3 days of treatment with octreotide, new episodes of obstruction occurred, resulting in a delay of the chemotherapy treatment. After 3 episodes of obstruction, we initiated treatment with a longer-acting somatostatin analogue, lanreotide Autogel® 120 mg, administered once every 4 weeks. The treatment with lanreotide Autogel is being continued, allowing for continuation of the chemotherapy without further episodes of intestinal subocclusion or obstruction. Until November 2013, the patient received eighteen 4-weekly injections of lanreotide Autogel and did not report side effects. This case report demonstrates the successful treatment of intestinal obstruction with lanreotide Autogel in a patient with adenocarcinoma.

show abstract

“…8,[25][26][27][28] Octreotide expedites NG tube removal, recovery of bowel function, and improvement in quality of life. [29][30][31][32] The medication should also be considered in cases of recurrent MBO that previously responded to the medication. Octreotide is considered the first-line agent in the palliative treatment of MBO, however the medication is costly.…”

Section: Antisecretory Agentsmentioning

confidence: 99%

Pharmacologic Management of Malignant Bowel Obstruction: When Surgery Is Not an Option

Hsu

Prommer

Murphy

et al. 2019

Journal of Hospital Medicine

View full text Add to dashboard Cite

Malignant bowel obstruction (MBO) complicates 3%-15% of cancers and often necessitates inpatient admission. Hospitalists are increasingly involved in treating patients with MBO and coordinating their care across multiple subspecialties. Direct resolution of the obstruction via surgical or interventional means is always preferable. When such options are not possible, pharmacological treatments are the mainstay of therapy. Medications such as somatostatin analogs, steroids, H2-blockers, and other modalities can be effective in palliation and possible resolution of obstruction. Awareness of these pharmacologic therapies can aid hospitalists in treating patients who are confronted with this devastating condition.

show abstract

SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction

Cited by 38 publications

References 17 publications

Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution

Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution

The Use of Lanreotide Autogel® in the Treatment of Intestinal Obstruction in a Patient with Adenocarcinoma

Pharmacologic Management of Malignant Bowel Obstruction: When Surgery Is Not an Option

Contact Info

Product

Resources

About